TriangleDISEASE & TREATMENT SETTING
Rubraca: metastatic Prostate Cancer with BRCA mutation after prior therapy
Source-derived catalogue. This is not a treatment recommendation or a personalised trial match.
Exact scope
Treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor-directed therapy and a taxane-based chemotherapy
Broader topic: Prostate Cancer
- Source population
- Not part of this definition
- Disease extent
- metastatic
- Treatment line
- Not part of this definition
- Stage
- Not part of this definition
- Resectability
- Not part of this definition
Biomarkers, prior therapy and derivation
- molecular
- gene
- BRCA
- alteration
- mutation
- status
- present
- prior therapy
- class
- who have been treated with androgen receptor-directed therapy and a taxane-based chemotherapy
- status
- required
- derivation status
- source-attested
- derivation note
- Scoped from the FDA approved indication for Rubraca (rucaparib) (accelerated-approval table). Only dimensions stated in that wording are part of this definition.
- source wording
- Treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor-directed therapy and a taxane-based chemotherapy
Study evidence for this setting
No linked study matches these filters. This is a source-coverage gap, not evidence that there are no treatment options.
Source relationships and population-mapping limitations
- bindings
- mappings
Download this complete draft source relationship record →
Preserved source evidence · Not medical advice